Figure 4 | Scientific Reports

Figure 4

From: Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer

Figure 4

Clinical outcomes of abiraterone (n = 14) and enzalutamide (n = 24) therapy according to AR aberrations. (a) Waterfall plot of %PSA change from baseline at 12 weeks stratified by AR status for abiraterone. (b) Kaplan-Meier analysis of PSA-PFS in patients treated with abiraterone. Median PSA-PFS in the patients with AR amplification, L702H, H875Y or T878A in cfDNA tended to be shorter than those without these aberrations (median 66.5 days versus 342 days, p = 0.049 by Wilcoxon test and p = 0.087 by log-rank test). (c) Waterfall plot of %PSA change from baseline at 12 weeks stratified by AR status for enzalutamide. (d) Kaplan-Meier analysis of PSA-PFS in patients treated with enzalutamide. Median PSA-PFS was not significantly associated with AR status in cfDNA (median 205 days versus not reached, p = 0.212 by Wilcoxon test and p = 0.117 by log-rank test).

Back to article page